Table 5.
H3R antagonist 2-18-induced vertebral abnormalities in mouse fetuses
| Saline | GD 8 (i.p. treated)
|
GD 8 (orally treated)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.5 mg | 15 mg | 30 mg | 60 mg | 15×3 mg | 7.5 mg | 15 mg | 30 mg | 60 mg | 15×3 mg | ||
| No of skeletons examined | 42 | 38 | 37 | 40 | 38 | 36 | 37 | 39 | 41 | 38 | 42 |
| Cervical arch 7–7 | 42 (100.0) | 38 (100.0) | 37 (100.0) | 40 (100.0) | 38 (100.0) | 36 (100.0) | 37 (100.0) | 39 (100.0) | 41 (100.0) | 38 (100.0) | 42 (100.0) |
| Cervical body 7 | 40 (95.2) | 34 (89.5) | 34 (91.9) | 38 (95.0) | 36 (94.7) | 33 (91.7) | 34 (91.9) | 36 (92.3) | 39 (95.1) | 36 (94.7) | 38 (90.5) |
| 0–2 | 1 (2.4) | 3 (7.9)* | 1 (2.7) | 1 (2.5) | 1 (2.6) | 1 (2.8) | 2 (5.4) | 2 (5.1) | 1 (2.4) | 1 (2.6) | 2 (4.8) |
| 3–6 | 1 (2.4) | 1 (2.6) | 2 (5.4) | 1 (2.5) | 1 (2.6) | 2 (5.6) | 1 (2.7) | 1 (2.5) | 1 (2.4) | 1 (2.6) | 2 (4.8) |
| Body with unossified/hypoplastic | |||||||||||
| 2–6 | 2 (4.8) | 2 (5.3) | 2 (5.4) | 4 (10.0)* | 1 (2.6) | 1 (2.8) | 3 (8.1) | 1 (2.6) | 2 (4.9) | 0 | 1 (2.4) |
| 7 body | 1 (2.4) | 2 (5.3) | 2 (5.4) | 1 (2.5) | 0 | 1 (2.8) | 1 (2.7) | 0 | 0 | 0 | 1 (2.4) |
| Thoracic arch 13–13 | 42 (100.0) | 38 (100.0) | 37 (100.0) | 40 (100.0) | 38 (100.0) | 36 (100.0) | 37 (100.0) | 39 (100.0) | 41 (100.0) | 38 (100.0) | 42 (100.0) |
| < or >13–13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Thoracic body 13 | 42 (100.0) | 38 (100.0) | 37 (100.0) | 40 (100.0) | 38 (100.0) | 36 (100.0) | 37 (100.0) | 39 (100.0) | 41 (100.0) | 38 (100.0) | 42 (100.0) |
| Lumbar arch 6 | 42 (100.0) | 38 (100.0) | 37 (100.0) | 40 (100.0) | 38 (100.0) | 36 (100.0) | 37 (100.0) | 39 (100.0) | 41 (100.0) | 38 (100.0) | 42 (100.0) |
| < or >6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lumbar body 6 | 42 (100.0) | 38 (100.0) | 37 (100.0) | 40 (100.0) | 38 (100.0) | 36 (100.0) | 36 (97.3) | 39 (100.0) | 41 (100.0) | 38 (100.0) | 42 (100.0) |
| < or >6 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2.7) | 0 | 0 | 0 | 0 |
| Sacral arch 6 | 42 (100.0) | 38 (100.0) | 37 (100.0) | 40 (100.0) | 38 (100.0) | 36 (100.0) | 37 (100.0) | 39 (100.0) | 41 (100.0) | 38 (100.0) | 42 (100.0) |
| Sacral body 6 | 42 (100.0) | 38 (100.0) | 36 (97.3) | 40 (100.0) | 38 (100.0) | 35 (97.2) | 37 (100.0) | 39 (100.0) | 41 (100.0) | 38 (100.0) | 41 (97.6) |
| >6 | 0 | 0 | 1 (2.7) | 0 | 0 | 1 (2.8) | 0 | 0 | 0 | 0 | 1 (2.4) |
| Coccygeal vertebrae-arch | |||||||||||
| 0–4 | 10 (23.8) | 13 (34.2) | 13 (35.1) | 14 (35.0) | 11 (28.9) | 13 (36.1) | 13 (35.1) | 14 (35.9) | 13 (31.7) | 10 (26.3) | 13 (31.0) |
| 5–7 | 32 (76.2) | 25 (65.8) | 24 (64.9) | 26 (65.0) | 27 (71.1) | 23 (63.9) | 24 (64.9) | 25 (64.1) | 28 (68.3) | 28 (73.7) | 29 (69.0) |
| Body 0–4 | 12 (28.6) | 14 (36.8) | 16 (43.3)* | 12 (30.0) | 11 (28.9) | 12 (33.3) | 12 (32.4) | 13 (33.3) | 13 (31.7) | 12 (31.6) | 13 (31.0) |
| 5–9 | 30 (71.4) | 24 (63.2) | 23 (57.9) | 28 (70.0) | 27 (71.1) | 24 (66.7) | 25 (67.6) | 26 (66.7) | 28 (68.3) | 26 (68.4) | 29 (69.0) |
|
| |||||||||||
| Saline |
GD 13 (i.p. treated)
|
GD 13 (orally treated)
|
|||||||||
| 7.5 mg | 15 mg | 30 mg | 60 mg | 15×3 mg | 7.5 mg | 15 mg | 30 mg | 60 mg | 15×3 mg | ||
|
| |||||||||||
| No of skeletons examined | 39 | 40 | 42 | 36 | 40 | 38 | 38 | 43 | 41 | 38 | 37 |
| Cervical arch 7–7 | 39 (100.0) | 40 (100.0) | 42 (100.0) | 36 (100.0) | 40 (100.0) | 38 (100.0) | 38 (100.0) | 43 (100.0) | 41 (100.0) | 38 (100.0) | 37 (100.0) |
| Cervical body 7 | 37 (94.9) | 36 (90.0) | 38 (90.5) | 33 (91.7) | 38 (95.0) | 35 (92.1) | 35 (92.1) | 39 (90.7) | 38 (92.7) | 36 (94.7) | 35 (94.6) |
| 0–2 | 1 (2.6) | 2 (5.0) | 2 (4.8) | 1 (2.8) | 1 (2.5) | 2 (5.3) | 2 (5.3) | 3 (7.0) | 2 (4.9) | 1 (2.6) | 1 (2.7) |
| 3–6 | 1 (2.6) | 2 (5.0) | 2 (4.8) | 2 (5.6) | 1 (2.5) | 1 (2.6) | 1 (2.6) | 1 (2.3) | 1 (2.4) | 1 (2.6) | 1 (2.7) |
| Body with unossified/hypoplastic | |||||||||||
| 2–6 | 1 (2.6) | 2 (5.0) | 2 (4.8) | 1 (2.8) | 1 (2.5) | 2 (5.3) | 1 (2.6) | 3 (7.0)* | 1 (2.4) | 0 | 2 (5.4) |
| 7 body | 1 (2.6) | 1 (2.5) | 1 (2.4) | 1 (2.8) | 0 | 1 (2.6) | 1 (2.6) | 0 | 0 | 1 (2.6) | 1 (2.7) |
| Thoracic arch 13–13 | 39 (100.0) | 40 (100.0) | 42 (100.0) | 36 (100.0) | 40 (100.0) | 38 (100.0) | 38 (100.0) | 43 (100.0) | 41 (100.0) | 38 (100.0) | 37 (100.0) |
| < or >13–13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Thoracic body 13 | 39 (100.0) | 40 (100.0) | 42 (100.0) | 36 (100.0) | 40 (100.0) | 38 (100.0) | 38 (100.0) | 43 (100.0) | 41 (100.0) | 38 (100.0) | 37 (100.0) |
| Lumbar arch 6 | 39 (100.0) | 40 (100.0) | 42 (100.0) | 36 (100.0) | 40 (100.0) | 38 (100.0) | 38 (100.0) | 43 (100.0) | 41 (100.0) | 38 (100.0) | 37 (100.0) |
| < or >6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lumbar body 6 | 39 (100.0) | 40 (100.0) | 41 (97.6) | 36 (100.0) | 40 (100.0) | 37 (97.4) | 37 (97.4) | 43 (100.0) | 41 (100.0) | 38 (100.0) | 37 (100.0) |
| < or >6 | 0 | 0 | 1 (2.4) | 0 | 0 | 1 (2.6) | 1 (2.6) | 0 | 0 | 0 | 0 |
| Sacral arch 6 | 39 (100.0) | 40 (100.0) | 42 (100.0) | 36 (100.0) | 40 (100.0) | 38 (100.0) | 38 (100.0) | 43 (100.0) | 41 (100.0) | 38 (100.0) | 37 (100.0) |
| Sacral body 6 | 39 (100.0) | 40 (100.0) | 41 (97.6) | 36 (100.0) | 40 (100.0) | 38 (100.0) | 38 (100.0) | 43 (100.0) | 41 (100.0) | 38 (100.0) | 36 (97.3) |
| >6 | 0 | 0 | 1 (2.4) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2.7) |
| Coccygeal vertebrae arch | |||||||||||
| 0–4 | 11 (28.2) | 15 (37.5) | 13 (31.0) | 14 (38.9) | 12 (30.0) | 14 (36.8) | 13 (34.2) | 15 (34.9) | 14 (34.1) | 11 (28.9) | 15 (40.5) |
| 5–7 | 28 (71.8) | 25 (62.5) | 29 (69.0) | 22 (61.1) | 28 (70.0) | 24 (63.2) | 25 (65.8) | 28 (65.1) | 27 (65.9) | 27 (71.1) | 22 (59.5) |
| Body 0–4 | 10 (25.6) | 12 (30.0) | 16 (38.1) | 12 (33.3) | 10 (25.0) | 13 (34.2) | 12 (31.6) | 14 (32.6) | 13 (31.7) | 10 (26.3) | 12 (32.4) |
| 5–9 | 29 (74.4) | 28 (70.0) | 22 (61.9) | 24 (66.7) | 30 (75.0) | 25 (65.8) | 26 (68.4) | 29 (67.4) | 28 (68.3) | 28 (73.7) | 25 (67.6) |
Notes: Numerals in parentheses are percentages;
*
P<0.05, compared to the control values (bold values).
Abbreviations: i.p., intraperitoneal; GD, gestation day.